Eris Lifesciences
Manufacturing · India · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
Shivarth Ambit plot no 142/2 Ramdas Road...Phone Number
+91 7969661000Website
www.eris.co.inRevenue
$335.4 MillionStock Symbol
ERISIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Eris Lifesciences
Eris Lifesciences Ltd is a prominent Indian pharmaceutical company specializing in branded formulations, particularly in the cardio-metabolic sector. The company offers a diverse range of products across various therapeutic areas including anti-diabetes, cardiovascular health, dermatology, and gynecology. Eris is committed to improving patient care through innovative initiatives and pioneering studies aimed at chronic lifestyle-related diseases. Their target clients include healthcare professionals and patients across India, with a focus on enhancing health outcomes.Explore more
Eris Lifesciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eris Lifesciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Eris Lifesciences launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Eris Lifesciences has new funding data
Click to see if Eris Lifesciences had a recent Job posting/layoffs
Earning: See what the market has to say on Eris Lifesciences recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Eris Lifesciences
Check out if Eris Lifesciences is spiking on competitors!
Check if Eris Lifesciences has recently received funding, and reach out quickly before it becomes old news!
Eris Lifesciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Eris Lifesciences
Find 2 more new buyers
Explore company insights
Get a deeper look into Eris Lifesciences's structure, leadership, and market position:
Company Profile Activity
Activity Insights
Eris Lifesciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eris Lifesciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eris Lifesciences.
Eris Lifesciences Tech Stack
A closer look at the technologies used by Eris Lifesciences
See more technologies
Most Recent Scoops
Product Launch
Eris Lifesciences has announced the launch of Wegovy GX, an obesity SKU, with billing expected by end of the current month and the full market launch scheduled for next month.
Product Launch, Pharmaceuticals
Pain Point
Eris Lifesciences is experiencing operational disruptions due to ongoing remediation work at one of its facilities, which is expected to compress EBITDA margins, with revenue impact anticipated to be limited. The company has guided for neutral to low single-digit growth for the affected period, with greater clarity expected by the end of Q2.
Earnings, Facilities Maintenance, Finance, Risk
Project
Eris Lifesciences has announced plans to launch esaxerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), with visibility for launch in the first fortnight of August following earlier delays in approvals.
Earnings
Eris Lifesciences has reported that domestic formulation gross margins, which held in a 76% to 77% band throughout the prior year, contracted in Q1 of the current year due to a product mix shift toward insulins and biologics, with insulin gross margins at 30% to 31%. The company expects Q2 gross margins to remain in a similar range, with improvement anticipated from Q3 and a potential return to prior-year levels by Q4, contingent on production commencing at the Bhopal facility next month.
Earnings, Finance, Manufacturing Operations
Earnings
Earnings, Forecasting, Finance
Eris Lifesciences News & Media
Eris Lifesciences Sells Entire Stake In Its Subsidiaries For Rs 861.9 Crore - NDTV Profit
Eris Lifesciences Ltd. has sold its entire stake in two of its subsidiaries to Eris Therapeutics Ltd. for Rs 861.9 crore. The company is expected to complete the stake sale in Eris Oaknet Healthcare Pvt. and Aprica Healthcare Ltd. by March 31, according to an exchange on Thursday.Motilal Oswal Financial Services Acquires 1.52% Stake In Eris Lifesciences - NDTV Profit
A public shareholder of Eris Lifesciences Ltd. on Thursday offloaded 1.46% stake for Rs 270 crore in the company through open market transactions. One of the public shareholders of the pharma major, Rakesh Shah, sold 20 lakh shares on Thursday at Rs 1,350 apiece, according to NSE bulk deal data. As of June 2024, he held a 4.88% stake in the company.Individual sells 2 per cent stake in Eris Lifesciences for Rs 188 crore
The shares were sold at an average price of Rs 697 apiece, taking the aggregate transaction size to Rs 188.19 crore.Eris Lifesciences buys dermatology brands from Dr Reddy's for Rs 275 crore
In January Eris had bought some derma brands from Glenmark Pharma as well
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eris Lifesciences
Sign Up For FreeTo access detailed company insights
Eris Lifesciences Ltd is a prominent Indian pharmaceutical company specializing in branded formulations, particularly in the cardio-metabolic sector. The company offers a diverse range of products across various therapeutic areas including anti-diabetes, cardiovascular health, dermatology, and gynecology. Eris is committed to improving patient care... Read More
